Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate the Feasibility of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Vaccine Administered as a 3 Dose Primary Vaccination Course at 6, 10 & 14 Weeks of Age

NCT00291967 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00291967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00291967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate the Feasibility of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Vaccine Administered as a 3 Dose Primary Vaccination Course at 6, 10 & 14 Weeks of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2002
Completion date
Not reported
Enrollment
525
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, hepatitis b, hib diseases, neisseria meningitidis serogroups a & c diseases, pertussis, tetanus